Additional Study Information: INCB106385 and INCMGA00012 are drugs being studied by Incyte Corporation for use in the treatment of advanced cancer. These study drugs are known as immune therapies, which are designed to help your immune system become more active and possibly fight your cancer. INCB106385 will be tested either alone (monotherapy) or in combination with INCMGA00012. The purpose of this trial is to test the safety and tolerability of the monotherapy or combination therapy, find out what effects the study drugs have on people and their cancer, and to select the safe and tolerable dose of INCB106385 as monotherapy and in combination with INCMGA00012. Cancers may include bladder cancer, breast cancer, colon and rectal cancer, esophageal cancer, ovarian cancer, head and neck/oral cancers, lung cancer, pancreatic cancer, and prostate cancer.